We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), ...
Efficacy and safety of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A prospective, single-arm, phase II trial. This is an ASCO Meeting ...
Octreotide scintigraphy versus DOTATOC PET: Concordance of Krenning scores and implications on PRRT treatment eligibility. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Peluntamig (PT217) targets DLL3 and CD47, receiving FDA orphan drug and fast track designations for SCLC and NEC. The SKYBRIDGE trial evaluates peluntamig's safety, tolerability, and efficacy in ...
Neuroendocrine carcinomas (NECs), which include small-cell lung cancer (SCLC), are a highly heterogeneous group of aggressive cancers with poor prognosis, noted Martin Wermke, MD, of TU Dresden ...
DUBLIN--(BUSINESS WIRE)--The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. Delta-like ...
Molecular Partners announced positive IND-enabling data for MP0712 and preclinical findings for novel targeted Radio-DARPins at AACR 2025. Molecular Partners AG announced positive IND-enabling data ...
Please provide your email address to receive an email when new articles are posted on . MADRID — A novel T-cell engager appeared safe and exhibited efficacy as treatment for neuroendocrine tumors, ...
BeOne Medicines is monetizing its stake in Amgen’s first-in-class lung cancer drug Imdelltra for up to $950 million. Royalty Pharma will pay BeOne $885 million upfront for certain royalty payments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results